Mymetics Corp (MYMX)

[Work Harder]

Excited to speak at the IMAPAC Asia Vaccine Conference about
@TCHGlobalHealth

@BCM_TropMed
advances of a #COVID19 #vaccine. Tomorrow evening Nov. 2 at 9:15pm US Central time or Nov 3 at 11:15 am SGT Here is the registration link if interested: https://imapac.com/en/vwa-2020-registration-page/

https://twitter.com/mebottazzi/status/1322909465755197440

https://www.imapac.com/en/business_conferences/vaccine-world-asia-congress/

Speakers

https://www.imapac.com/en/business_conferences/vaccine-world-asia-congress/?lists=speakers

Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice

Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, Netherlands

EDITED BY

Raghavan Varadarajan

Indian Institute of Science (IISc), India

https://www.frontiersin.org/articles/10.3389/fimmu.2018.02350/full

Multiplying Efforts To Beat Covid- 19
Bio Spectrum|May 2020

https://www.magzter.com/article/Business/Bio-Spectrum/Multiplying-Efforts-To-Beat-Covid-19

Bengaluru based Indian Institute of Science (IISc) is also contributing to the vaccine space through its startup Mynvax, founded by Dr Raghavan Varadarajan and Dr Gautham Nadig. The team is trying to design and test variants of the spike glycoprotein as vaccine candidates against COVID-19. For this effort, the startup is seeking a funding support of Rs15 crore.

“With critical, catalytic funding and support from the Bill and Melinda Gates Foundation, a number of spike protein derivatives have been designed and characterized at IISc. These are being tested in animal models. The design which shows the best results in animals will be advanced to development of production technology, safety and toxicity testing, followed by GMP manufacturing for use in Phase-1 clinical trials. We estimate that atleast 100 million doses will be required to meet India’s requirement if the SARS- CoV-2 infection persists for the medium to long-term”, reveals Dr Raghavan Varadarajan, Professor, Molecular Biophysics Unit, IISc, Bengaluru.